Tiotropium HandiHaler&amp;reg; and Respimat&amp;reg; in&amp;nbsp;COPD:&amp;nbsp;a pooled safety analysis

Christine Winchester; David Halpin; Ronald E Dahl; Christoph Hallmann; Achim Mueller; Donald P. Tashkin

doi:10.2147/copd.s75146

Abstract

1 min read

This analysis indicates that tiotropium is associated with lower rates of AEs, SAEs, and similar rates of FAEs than placebo when delivered via HandiHaler(®) or Respimat(®) (overall and separately) in patients with COPD.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2015

Exacerbator subtypes in the TIOtropium Safety and Performance In Respimat (TIOSPIR™) trial

Christian Geßner, Peter M. Calverley, Daniel Dusser, Robert A. Wise, Gordon Pledger, Ronald E Dahl, Achim Mueller, Jessica Montero Caballero, Antonio Anzueto

Article2015

P150 Once-daily tiotropium Respimat® reduces risk of severe asthma exacerbation and asthma worsening in symptomatic asthma, independent of allergic and inflammatory status

Ronald E Dahl, Thomas B. Casale, Mark Vandewalker, Hendrik Schmidt, Michael E. Engel, P. Moroni-Zentgraf, Huib A.M. Kerstjens

Article2002

Tiotropium bromide: A novel once-daily anticholinergic bronchodilator for the treatment of COPD

Trevor T. Hansel, Peter J Barnes

Article2018

Efficacy and safety profile of xanthines in COPD: a network meta-analysis

Mario Cazzola, Luigino Calzetta, Peter J Barnes, Gerard J. Criner, Fernando J. Martínez, Alberto Papi, Maria Gabriella Matera

Article2008

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

Meletios A Dimopoulos, Paul G. Richardson, Rudolf Schlag, Nuriet K. Khuageva, Ofer Shpilberg, Efstathios Kastritis, Martin Kropff, Maria Teresa Petrucci, Michel Delforge, Julia A. Alexeeva, Rik Schots, Tamás Masszi, María‐Victoria Mateos, William Deraedt, Kevin Liu, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel